Citius Oncology (CTOR) Interest Expenses (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Interest Expenses data on file, last reported at $6.9 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 22559.54% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 3137.11% increase from a year earlier, with the FY2025 full-year figure at $5.4 million, down 54.11% from the prior year.
• Interest Expenses for Q1 2026 stood at $6.9 million, down from $33.3 million in the prior quarter.
• Over the last five years, Interest Expenses for CTOR reached as high as $46.1 million in Q2 2025 and fell as low as $30368.0 in Q4 2023.
• Historically, Interest Expenses has averaged $9.3 million across 4 years, with a median of $470000.0 in 2024.
• On a YoY basis, Interest Expenses climbed as much as 50449.01% in 2025 and fell as far as 99.14% in 2025.
• Year by year, Interest Expenses stood at $30368.0 in 2023, then surged by 1447.68% to $470000.0 in 2024, then soared by 6976.46% to $33.3 million in 2025, then sank by 79.31% to $6.9 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $6.9 million in Q1 2026, $33.3 million in Q4 2025, and $101143.0 in Q3 2025.